Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four Cases
スポンサーリンク
概要
- 論文の詳細を見る
We report on the outcome of 4 patients with therapy-resistant systemic mast cell activation disease (MCAD) treated with the anti-IgE monoclonal antibody omalizumab in compassionate use. Two patients achieved an impressive persistent clinical response to treatment with omalizumab. In the third patient symptoms gradually improved. In the fourth patient omalizumab treatment had to be discontinued due to intolerable mast cell mediator-induced symptoms. In conclusion, omalizumab can lessen the intensity of the symptoms of systemic MCAD. Hence, omalizumab should be considered as a therapeutic option in cases of systemic MCAD that are resistant to evidence-based therapy.
論文 | ランダム
- Numerical simulation for the prediction of the plate motions : Effects of lateral viscosity variations in the lithosphere
- 石川純治他訳, 『会計学・財務論の研究方法』, 同文舘, A5判, 212頁, 1995年, 3.500円
- 5187 知立市民ホールの基本計画段階における市民参加
- 5052 マクロ経済指標に基づく市町村の社会教育費に関する考察
- 新造船要目表改訂小委員会の思い出